Bristol-Myers Squibb Company (BMY)
Chart Events
Performance Outlook
| Previous Close | 74.86 |
| Open | 74.39 |
| Bid | 74.59 x 1000 |
| Ask | 74.60 x 800 |
| Day's Range | 74.33 - 75.51 |
| 52 Week Range | 53.22 - 80.59 |
| Volume | |
| Avg. Volume | 11,916,808 |
| Market Cap | 159.077B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 24.75 |
| EPS (TTM) | 3.01 |
| Earnings Date | Oct 26, 2022 |
| Forward Dividend & Yield | 2.16 (2.88%) |
| Ex-Dividend Date | Jun 30, 2022 |
| 1y Target Est | 81.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BMY
Related Research
- Bristol-Myers Squibb CompanyAnalyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.RatingFair ValueEconomic Moat7 days agoMorningstar
- Investor's Business Daily
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why
There's no better time than to build a strong watchlist during a serious market correction. This story covers five NYSE stocks to watch and consider buying. In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.
- MarketWatch
10 defensive stocks that can also provide you with growth and dividends over the long term
Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.
- Benzinga
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
Bristol Myers Squibb Co (NYSE: BMY) and 2seventy bio Inc (NASDAQ: TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma. The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen. The interim analysis demonstrated a statistically significant improvement in progression-free survival. Related Content:
